Pricing Log in Create free account
Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue
+3,749.2%
EPS
+549.1%
Free cash flow
+839.7%

Quarter to June 2026, against a year earlier

132.10 3.16 −2.34%
Market cap
$8.8B
P/E
111×
Fwd P/E
31.2×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Protagonist Therapeutics, Inc. (PTGX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Protagonist Therapeutics, Inc. (PTGX) trades at a EV/Sales of 28.9×. Over the past ten years it has ranged from −1,712× (November 2019) to 500× (February 2020); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 109× 2,296.89%
FY2024 4.5× (79.35%)
FY2023 21.9× 231.27%
FY2022 6.6× (85.71%)
FY2021 46.3× 233.64%
FY2020 13.9× (94.59%)
FY2019 257× 36,574.55%
FY2018 0.7× —
FY2017 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 25.9× (69.63%)
Mar 2026 85.4× (21.36%)
Dec 2025 109× 518.79%
Sep 2025 17.5× 24.41%
26 more quarters

Against its own ten years

Low −1,712× High 500×
Ten-year median 11.9×
Current reading's percentile 68

EV/Sales against peers

Company EV/Sales
CAI Caris Life Sciences,�Inc. compare 6.8×
MDGL Madrigal Pharmaceuticals, Inc. compare 7.8×
TGTX TG Therapeutics, Inc. compare 10.5×
KRYS Krystal Biotech, Inc. compare 17.0×
TWST Twist Bioscience Corporation compare 17.3×
PTGX Protagonist Therapeutics, Inc. 28.9×
IBRX ImmunityBio, Inc. compare 56.5×
CYTK Cytokinetics, Incorporated compare 65.9×
SYRE Spyre Therapeutics, Inc. compare 7,143×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PTGX